Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

Astrazeneca (AZN) closed at $84.69 in the latest trading session, marking a +1.03% move from the prior day. This change outpaced the S&P 500's 0.53% gain on the day. Elsewhere, the Dow gained 0.52%, while the tech-heavy Nasdaq added 0.52%. Shares of the pharmaceutical witnessed a gain of 8.77% over the previous month, beating the performance of the Medical sector with its gain of 2.87%, and the S&P 500's gain of 0.71%.Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 6, 2025. The company is predicted to post an EPS of $1.14, indicating a 9.62% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $14.86 billion, up 9.57% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of $4.58 per share and a revenue of $58.6 billion, demonstrating changes of +11.44% and +8.37%, respectively, from the preceding year. Investors should also take note of any recent adjustments to analyst estimates for Astrazeneca. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Astrazeneca currently has a Zacks Rank of #3 (Hold). Investors should also note Astrazeneca's current valuation metrics, including its Forward P/E ratio of 18.3. For comparison, its industry has an average Forward P/E of 20.11, which means Astrazeneca is trading at a discount to the group. It is also worth noting that AZN currently has a PEG ratio of 1.54. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. AZN's industry had an average PEG ratio of 1.77 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 83, this industry ranks in the top 34% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow AZN in the coming trading sessions, be sure to utilize Zacks.com. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks